Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID‐19) pandemic: A case series. Issue 1 (13th January 2022)

• Record Type: Journal Article
• Authors: Vijayan, Sooraj; Hwangbo, Kyungmin; Barkham, Nick
• Is Part Of: Clinical case reports. Volume 10:Issue 1(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-01-13
• Subjects: ankylosing spondylitis -- case report -- case series -- COVID‐19 -- CT‐P13 -- CT‐P13 SC -- infliximab -- infliximab SC -- infliximab subcutaneous -- real‐world evidence; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.5233
• Languages: English
• ISSNs: 2050-0904

Abstract

Abstract: The COVID‐19 pandemic emphasized the utility of subcutaneous (SC) biologics for pressured healthcare systems. The first SC form of infliximab, CT‐P13 SC, provided safe and effective treatment for ankylosing spondylitis in our case series, with increased convenience relative to intravenous treatment benefitting patients both during the pandemic and beyond.